Navigation Links
APIC Conference to address new CMS regulations
Date:4/17/2008

Washington, DC, April 17, 2008 The new Centers for Medicare & Medicaid Services (CMS) regulations that will eliminate or reduce payments for three hospital-acquired infections (HAIs) will be the subject of a two-day conference for healthcare executives and professionals sponsored by the Association for Professionals in Infection Control and Epidemiology (APIC). Mastering the New CMS Regulation: Implications for Infection Prevention & Control, takes place September 22-23, 2008 at the Crystal Gateway Marriott in Arlington, VA.

Beginning October 1, 2008, CMS will no longer reimburse hospitals for costs related to eight preventable conditions, including three HAIs: catheter-associated urinary tract infections (UTIs), catheter-associated blood stream infections, and mediastinitis (a deep infection following coronary artery bypass surgery). The APIC conference will present information on how leading institutions are managing the clinical and economic impact of the new HAI regulations and practical strategies to assist facilities with compliance.

We see this as an important opportunity to help clinical and administrative leaders work together to reduce infection, improve outcomes and preserve healthcare resources, said APIC Chief Executive Officer Kathy L. Warye. The conference will offer the most current information from CMS, as well as best practices and ways of approaching quality improvement to achieve reductions in HAIs.

Thomas Valuck, MD, JD, Director, Special Program Office for Value-Based Purchasing, CMS, will serve as conference keynote speaker. Additional presenters include Sanjay Saint, MD, MPH, Professor, Department of Internal Medicine, University of Michigan Health System; Daniel Varga, MD, Chief Medical Officer, SSM Healthcare, St. Louis, MO; Chesley Richards, MD, MPH, FACP, Deputy Director, Division of Healthcare Quality Promotion, CDC; Nellie Leon-Chisen, RHIA, Director, Coding and Classification, American Hospital Associ
'/>"/>

Contact: Liz Garman
egarman@apic.org
202-454-2604
Association for Professionals in Infection Control
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
2. Optimal Readings Selected to Present at CEDs 25th Annual Venture Conference
3. Edwards Lifesciences to Host Earnings Conference Call on April 22, 2008
4. HealthSouth Announces Date of 2008 First Quarter Earnings Conference Call
5. NHP Announces First Quarter Earnings Release Date and Conference Call/Webcast
6. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
7. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
8. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
9. HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call
10. Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice
11. NHMA, Office of Minority Health Unveil Findings of Summits to Eliminate Health Disparities at Conference April 17-20
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 4Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 2Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 3Health News:AHF Launches 'Public Health Division' 2Health News:AHF Launches 'Public Health Division' 3Health News:AHF Launches 'Public Health Division' 4Health News:'Making the Case:' special double issue of Critical Inquiry 2Health News:'Making the Case:' special double issue of Critical Inquiry 3Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2